News | April 10, 2026
Zeto gains FDA nod for new outpatient EEG system promising faster brain health testing
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
Patients with BRCA mutations often face aggressive disease and poor prognosis
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery
The newly established institute is equipped with advanced infrastructure designed to integrate multiple specialties under one roof
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The expansion includes a larger technical and service team and increased local procurement
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
